inriver Showcases Innovations and Customer Success at PIMpoint Europe 2023
9.5.2023 09:00:00 EEST | Business Wire | Press release
inriver, the leading software company powering the entire product journey with revenue-driving product information management (PIM) across every customer touchpoint, today unveiled a significant new product innovation and showcased leading brand partners at PIMpoint Europe 2023, its annual conference and the world’s largest product information management event.
This year’s event is highlighted by inriver’s new breed of PIM, an evolution of traditional product information management solutions. As a result of this new breed of PIM, inriver announced continued product innovation to the inriver PIM platform, including ChatGPT functionality to create efficiencies for augmenting product data, and further showcased the power of its now-available syndication capabilities. These innovations have allowed inriver to deliver even more operational efficiency, built-in digital shelf analytics, expanded sales opportunities, and greater sustainability benefits.
“We face unprecedented demand for more sustainability from brands, retailers, and manufacturers as a result of our increasingly circular economy. PIMpoint Europe 2023 comes at such a pivotal moment for our community,” said Niels Stenfeldt, inriver CEO. “As the world prepares for the European Union’s new Digital Product Passport initiative, the new breed of PIM turns global demands for supply chain transparency into new growth drivers for manufacturing companies. There is no better time to welcome our peers across so many industries for meaningful conversations for the future.”
Joining inriver are customer and partner showcases led by leading brands such as Michelin, Victorinox, Öob, Fluidra and more. These brands represent world-class PIM users that inriver helps create, enrich, and syndicate product information across a variety of channels and marketplaces.
Another brand, and inriver customer appearing at PIMpoint is Lantmännen, Northern Europe’s leader in agriculture, machinery, bioenergy and food products. Owned by 18,000 Swedish farmers and with 10,000 employees, Lantmännen has operations in over 20 countries and an annual revenue of approximately SEK 60 billion.
“Lantmännen has a long-term approach to farming, taking an active role in creating more sustainable energy and food supply. We take responsibility from field to fork and focus on issues that are of importance for sustainable, profitable, and thriving farming,” said Håkan Jägbrink, Platform Manager for the IT Commercial Backbone at Lantmännen. “As we are building a sustainable value chain across multiple companies and industries, Lantmännen requires our product data to be complete and accurate. The inriver PIM solution allows us to connect the data across people, processes, and our metadata structure for our 7 different companies. The inriver PIM’s flexible, elastic data model powers our product journey to drive efficiencies and cost reductons. Further, inriver is developing in exactly the right direction for our upcoming requirements.”
In addition to product innovations, brand, and partner showcases, inriver also announced the recipients of the 2022 inriver awards. The awards highlight organizations and individuals leading the industry and driving change in digital commerce and product information management. PIMpoint Europe Award winners:
- 2022 Alliance Ambassador of the Year, Global — Salesforce
- 2022 Alliance Partner of the Year, Global — Bynder
- 2022 Customer of the Year, EMEA — Fluidra
- 2022 Customer Ambassador of the Year, EMEA — Christopher Klumpp, Victorinox
- 2022 Partner of the Year, EMEA — Nexer
- 2022 Partner Project of the Year, EMEA — Nexer for Lantmännen
- 2022 Community Ambassador of the Year, Global — Mark Stuart-Walker, Luceco plc
“This has been a truly awe-inspiring year for the PIM community and the recipients of the 2022 inriver awards are not only being recognized for industry-leading PIM use cases, projects, and innovation but for their dedication to collaboration and business transformation,” said Brooke Cunningham, Chief Marketing Officer, inriver. “This year’s winning customers are leading from the front with their product information strategies, and these partners are committed to helping our joint customers power their entire product journeys. On behalf of the inriver leadership team, I want to thank each and every award recipient for their contribution to driving successful business outcomes.”
PIMpoint is made possible by the inriver valued partner ecosystem and the role it plays in delivering impactful customer stories, including the PIMpoint 2023 Global sponsors Optimizely and Nexer, as well as Europe sponsors Bynder, Delaware, Digizuite, Lengoo, Transperfect, Aprimo, Diamir Consulting, FotoWare, Geta, Immeo, Tietoevry, Etac, Avensia, ChannelEngine, Cypoint Inspire AB, Mad Max Consulting, Priint, and Xsarus.
In addition to customer and partner momentum in the Nordics market, inriver continues to invest in leadership and talent to support its local workforce. Ulrica Falkenberg has recently been appointed as Chief People and Culture Officer for the company based in Stockholm. An accomplished executive and Swedish national, Falkenberg most recently served as CHRO at Trustly, a digital payments company, and has served as an executive at Alumni Harvey Nash, an Executive Talent firm, as well as Max Mara Fashion Group.
About inriver
inriver powers the entire product journey at every touchpoint. The inriver configurable PIM solution, with built-in digital shelf analytics and integration capabilities, connects to your digital ecosystem with flexibility and ease, so it grows as your company grows. With more demands on product data than ever before, B2B and B2C enterprises need a PIM solution that supports the entire product cycle, from sourcing to decommissioning and every stage in between.
inriver helps brands, manufacturers, and retailers turn product information into strategic assets, maximizing profitability at every touchpoint for 1,600+ global brands. Headquartered in Malmö, Sweden, and with offices worldwide, inriver has a team of over 375 people ready to strengthen your product journey. For more information, visit inriver.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005195/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
